[1]王宁,刘又言,徐小凤,等.眼周基底细胞癌治疗方法研究进展[J].眼科新进展,2019,39(1):089-93.[doi:10.13389/j.cnki.rao.2019.0021]
　WANG Ning,LIU You-Yan,XU Xiao-Feng,et al.Recent advances in the treatment of periocular basal cell carcinoma[J].Recent Advances in Ophthalmology,2019,39(1):089-93.[doi:10.13389/j.cnki.rao.2019.0021]
点击复制

眼周基底细胞癌治疗方法研究进展/HTML
分享到：

《眼科新进展》[ISSN:1003-5141/CN:41-1105/R]

卷:
39卷
期数:
2019年1期
页码:
089-93
栏目:
文献综述
出版日期:
2019-01-05

文章信息/Info

Title:
Recent advances in the treatment of periocular basal cell carcinoma
作者:
王宁; 刘又言; 徐小凤; 王大庆
637000　四川省南充市，川北医学院附属医院眼科（王宁，刘又言，徐小凤，王大庆）（王宁现单位：629000　四川省遂宁市，遂宁市中心医院眼科）
Author(s):
WANG Ning; LIU You-Yan; XU Xiao-Feng; WANG Da-Qing
Department of Ophthalmology，Affiliated Hospital of North Sichuan Medical College （WANG Ning，LIU You-Yan，XU Xiao-Feng，WANG Da-Qing），Nanchong 637000，Sichuan Province，China；the Department of Ophthalmology，Suining Central Hospital（WANG Ning），Suining 629000，Sichuan Province，China
关键词:
眼周基底细胞癌; 治疗方式; 咪喹莫特; CO2; 光动力疗法
Keywords:
periocular basal cell carcinoma; treatment method; imiquimod; CO2; photodynamic therapy
分类号:
R777.1
DOI:
10.13389/j.cnki.rao.2019.0021
文献标志码:
A
摘要:
基底细胞癌（basal cell carcinoma，BCC）是眼睑最常见的恶性肿瘤，占所有眼睑恶性上皮肿瘤的90%，以下睑多见（50%）。BCC远处转移非常罕见，但易复发。虽然BCC死亡率低，如未及时诊治，可广泛破坏周围组织并向眶内浸润，甚至失明、容貌改变，影响患者的身心健康及生活质量。目前BCC的主要治疗方式包括手术治疗和非手术治疗，本文就目前常用的治疗方法做一综述。
Abstract:
Basal cell carcinoma （BCC） is the most common malignant tumor of the eyelid，accounting for 90% of all malignant epithelial tumors of the eyelid，and the lower eyelid is more common （50%）.Distant metastasis of BCC is rare but easy to relapse.Although the mortality rate of BCC is low，if not diagnosed and treated in time，it can destroy the surrounding tissues and infiltrate into the orbit extensively，even blindness，appearance changes，affecting the physical and mental health and quality of life of patients.Currently，the main treatment methods of BCC include surgical treatment and non-surgical treatment.After consulting the relevant literature，the commonly used treatment methods of BCC were reviewed in this article.

参考文献/References:

［1］　SALEH G M，DESAI P，COLLIN J R，IVES A，JONES T，HUSSAIN B.Incidence of eyelid basal cell carcinoma in England：2000-2010［J］.Br J Ophthalmol，2017，101（2）：209-212.
［2］　MARZUKA A G，BOOK S E.Basal cell carcinoma：pathogenesis，epidemiology，clinical features，diagnosis，histopathology，and management［J］.Yale J Biol Med，2015，88（2）：167-179.
［3］　HOORENS I，VOSSAERT K，ONGENAE K，BROCHEZ L.Is early detection of basal cell carcinoma worthwhile? Systematic review based on the WHO criteria for screening［J］.Br J Dermatol，2016，174（6）：1258-1265.
［4］　SUN M T，WU A，HUILGOL S C，SELVA D.Accuracy of Biopsy in Subtyping Periocular Basal Cell Carcinoma［J］.Ophthalmic Plast Reconstr Surg，2015，31（6）：449-451.
［5］　HARVEY D T，TAYLOR R S，ITANI K M，LOEWINGER R J.Mohs micrographic surgery of the eyelid：an overview of anatomy，pathophysiology，and reconstruction options［J］.Dermatol Surg，2013，39（5）：673-697.
［6］　NEWLANDS C，CURRIE R，MEMON A，WHITAKER S，WOOLFORD T.Non-melanoma skin cancer：United Kingdom National Multidisciplinary Guidelines［J］.J Laryngol Otol，2016，130（S2）：S125-S132.
［7］　PFEIFFER M J，PFEIFFER N，VALOR C.Descriptive study on basal cell eyelid carcinoma［J］.Arch Soc Esp Oftalmol，2015，90（9）：426-431.
［8］　CONNOLLY S M，BAKER D R，COLDIRON B M，FAZIO M J，STORRS P A，VIDIMOS A T，et al.AAD/ACMS/ASDSA/ASMS 2012 appropriate use criteria for Mohs micrographic surgery：a report of the American Academy of Dermatology，American College of Mohs Surgery，American Society for Dermatologic Surgery Association，and the American Society for Mohs Surgery［J］.J Am Acad Dermatol，2012，67（4）：531-550.
［9］　SUN M T，WU A，FIGUEIRA E，HUILGOL S，SELVA D.Management of periorbital basal cell carcinoma with orbital invasion［J］.Future Oncol，2015，11（22）：3003-3010.
［10］　FURDOVA A，LUKACKO P.Periocular Basal Cell Carcinoma Predictors for Recurrence and Infiltration of the Orbit［J］.J Craniofac Surg，2017，28（1）：e84-e87.
［11］　HO S F，BROWN L，BAMFORD M，SAMPATH R，BURNS J.5 years review of periocular basal cell carcinoma and proposed follow-up protocol［J］.Eye （Lond），2013，27（1）：78-83.
［12］　WETZIG T，WOITEK M，EICHHOM K，SIMON J C，PAASCH U.Surgical excision of basal cell carcinoma with complete margin control：outcome at 5-year follow-up［J］.Dermatology，2010，220（4）：363-369.
［13］　CIGNA E，TARALLO M，MARUCCIA M，SORVILLO V，POLLASTRINI A，SCUDERI N.Basal cell carcinoma：10 years of experience［J］.J Skin Cancer，2011，2011：476362.
［14］　SANTIAGO F，SERRA D，VIEIRA R，FIGUEIREDO A.Incidence and factors associated with recurrence after incomplete excision of basal cell carcinomas：a study of 90 cases［J］.J Eur Acad Dermatol Venereol，2010，24（12）：1421-1424.
［15］　FARHI D，DUPIN N，PALANGIE A，CARLOTTI A，AVRIL M F.Incomplete excision of basal cell carcinoma：rate and associated factors among 362 consecutive cases［J］.Dermatol Surg，2007，33（10）：1207-1214.
［16］　PALMER V M，WILSON P R.Incompletely excised basal cell carcinoma：residual tumor rates at Mohs re-excision［J］.Dermatol Surg，2013，39（5）：706-718.
［17］　LONGHI P，SERRA M P，ROBOTTI E.Incompletely excised basal cell carcinomas：Our guidelines［J］.Onco Targets Ther，2008，1：1-4.
［18］　KYRGIDIS A，VAHTSEVANOS K，TZELLOS T G，XIROU P，KITIKIDOU K，ANTONIADES K，et al.Clinical，histological and demographic predictors for recurrence and second primary tumours of head and neck basal cell carcinoma.A 1062 patient-cohort study from a tertiary cancer referral hospital［J］.Eur J Dermatol，2010，20（3）：276-282.
［19］　BEUTNER K R，GEISSE J K，HEIMAN D，FOX TL，GINKEL A，OWENS ML.Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream［J］.J Am Acad Dermatol，1999，41（6）：1002-1007.
［20］　ROOZEBOOM M H，ARITS A H，NELEMANS P J，KELLENRS-SMEETS N W.Overall treatment success after treatment of primary superficial basal cell carcinoma：a systematic review and meta-analysis of randomized and nonrandomized trials［J］.Br J Dermatol，2012，167（4）：733-756.
［21］　PAPASTEFANOU V P，RENE C.Secondary resistance to vismodegib after initial successful treatment of extensive recurrent periocular basal cell carcinoma with orbital invasion［J］.Ophthalmic Plast Reconstr Surg，2017，33（3S Suppl 1）：S68-S70.
［22］　GARCIA-MARTIN E，IDOIPE M，Gil L M，PUEYO V，ALFARO J，PABLO L E，et al.Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas［J］.J Ocul Pharmacol Ther，2010，26（4）：373-379.
［23］　CAMEIRO R C，DE MACEDO E M，MATAYOSHI S.Imiquimod 5% cream for the treatment of periocular basal cell carcinoma［J］.Ophthalmic Plast Reconstr Surg，2010，26（2）：100-102.
［24］　GARCIA-MARTIN E，GIL-ARRIBAS L M，IDOIPE M，ALFARO J，PUEYO V，PABLO L E，et al.Comparison of imiquimod 5% cream versus radiotherapy as treatment for eyelid basal cell carcinoma［J］.Br J Ophthalmol，2011，95（10）：1393-1396.
［25］　CANNON P S，O’DONNELL B，HUILGOL S C，SELVA D.The ophthalmic side-effects of imiquimod therapy in the management of periocular skin lesions［J］.Br J Ophthalmol，2011，95（12）：1682-1685.
［26］　MICALI G，LACARRUBBA F，NASCA M R，SCHWARTZ R A.Topical pharmacotherapy for skin cancer：part I.Pharmaco-logy［J］.J Am Acad Dermatol，2014，70（6）：961-965，977-978.
［27］　SMITH V，WALTON S.Treatment of facial basal cell carcinoma：a review［J］.J Skin Cancer，2011，2011：380371.
［28］　SANTOS G，GOULAO J.One-stage reconstruction of fullthick-ness lower eyelid using a Tripier flap lining by a septal mucochondral graft［J］.J Dermatolog Treat，2014，25（5）：446-447.
［29］　FURDOVA A，LUKACKO P.Periocular basal cell carcinoma predictors for recurrence and infiltration of the orbit［J］.J Craniofac Surg，2017，28（1）：e84-e87.
［30］　KAVOUSSI H，EBRAHIMI A.Treatment and cosmetic outcome of superpulsed CO2 laser for basal cell carcinoma［J］.Acta Dermatovenerol Alp Pannonica Adriat，2013，22（3）：57-61.
［31］　BANDIERAMONTE G，LEPERA P，MOGLIA D，BONO A，De VECCHI C，MILANI F.Laser microsurgery for superficial T1-T2 basal cell carcinoma of the eyelid margins［J］.Ophthalmology，1997，104（7）：1179-1184.
［32］　HUMPHREYS T R，MALHOTRA R，SCHARF M J，MARCUS S M，STARKUS L，CALEQARI K.Treatment of superficial basal cell carcinoma and squamous cell carcinoma in situ with a high-energy pulsed carbon dioxide laser［J］.Arch Dermatol，1998，134（10）：1247-1252.
［33］　EBRAHIMI A，REZAEI M，KAVOUSSI R，EIDIZADEH M，MADANI S H，KAVOUSSI H.Superpulsed CO2 laser with intraoperative pathologic assessment for treatment of periorbital basal cell carcinoma involving eyelash line［J］.Dermatol Res Pract，2014，2014：931657.
［34］　SZPRINGER E，LUTNICKI K，MARCINIAK A.Photodynamic therapy--mechanism and employment［J］.Ann Univ Mariae Curie Sklodowska Med，2004，59（2）：498-502.
［35］　BOTTO N，ROGERS G.Nontraditional management of basal cell carcinoma［J］.J Drugs Dermatol，2013，12（5）：525-532.
［36］　ZOU Y，ZHAO Y，YU J，LUO X，HAN J，YE Z，et al.Photodynamic therapy versus surgical excision to basal cell carcinoma：meta-analysis［J］.J Cosmet Dermatol，2016，15（4）：374-382.
［37］　ROOZEBOOM M H，AARDOOM M A，NELEMANS P J，THISSEN M R，KELLENERS-SMEETS N W，KUIJPERS D I，et al.Fractionated 5-aminolevulinic acid photodynamic therapy after partial debulking versus surgical excision for nodular basal cell carcinoma：a randomized controlled trial with at least 5-year follow-up［J］.J Am Acad Dermatol，2013，69（2）：280-287.
［38］　WANG H，XU Y，SHI J，GAO X，GENG L.Photodynamic thera-py in the treatment of basal cell carcinoma：a systematic review and meta-analysis［J］.Photodermatol Photoimmunol Photomed，2015，31（1）：44-53.
［39］　PUCCIONI M，SANTORO N，GIANSANTI F，UCCI F，ROSSI R，LOTTI T，et al.Photodynamic therapy using methyl aminolevulinate acid in eyelid basal cell carcinoma：a 5-year follow-up study［J］.Ophthal Plast Reconstr Surg，2009，25（2）：115-118.
［40］　ATTILI S K，IBBOTSON S H，FLEMING C.Role of non-surgical therapies in the management of periocular basal cell carcinoma and squamous intra-epidermal carcinoma：a case series and review of the literature［J］.Photodermatol Photoimmunol Photomed，2012，28（2）：68-79.
［41］　LEWIN J M，CARUCCI J A.Advances in the management of basal cell carcinoma［J］.F1000Prime Rep，2015，7：53
［42］　PONTORIERO A，IATI G，CONTI A，MINUTOLI F，BOTTARI A，PERGOLIZZI S，et al.Treatment of periocular basal cell carcinoma using an advanced stereotactic device［J］.Anticancer Res，2014，34（2）：873-875.
［43］　PAMPENA R，PALMIERI T，KYRGIDIS A，RAMUNDO D，IOTTI C，LALLAS A，et al.Orthovoltage radiotherapy for nonmelanoma skin cancer （NMSC）：Comparison between 2 different schedules［J］.J Am Acad Dermatol，2016，74（2）：341-347.
［44］　CEILLEY R I.Mechanisms of action of topical 5-fluorouracil：review and implications for the treatment of dermatolo-gical disorders［J］.J Dermatolog Treat，2012，23（2）：83-89.
［45］　ARITS A H，MOSTERD K，ESSERS B A，SPOORENBERG E，SOMMER A，DE ROOIJ M J，et al.Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma：a single blind，non-inferiority，randomised controlled trial［J］.Lancet Oncol，2013，14（7）：647-654.
［46］　YIN V T，ESMAELI B.Targeting the hedgehog pathway for locally advanced and metastatic basal cell carcinoma［J］.Curr Pharm Des，2017，23（4）：655-659.
［47］　KESERU M，GREEN S，DULZ S.Vismodegib therapy for perio-cular basal cell carcinoma［J］.Klin Monbl Augenheilkd，2017，234（1）：64-69.
［48］　JACOBSEN A A，ALDAHAN A S，HUGHES O B，SHAH V V，STRASSWIMMER J.Hedgehog pathway inhibitor therapy for locally advanced and metastatic basal cell carcinoma：a systematic review and pooled analysis of interventional studies［J］.JAMA Dermatol，2016，152（7）：816-824.
［49］　ERDEM G U，SENDUR M A，OZDEMIR N Y，YAZICI O，ZENGIN N.A comprehensive review of the role of the hedgehog pathway and vismodegib in the management of basal cell carcinoma［J］.Curr Med Res Opin，2015，31（4）：743-756.
［50］　TANG J Y，ALLY M S，CHANANA A M，MACKAY-WIGGAN J M，ASZTERBAUM M，LINDGREN J A，et al.Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome：final results from the multicentre，randomised，double-blind，placebo-controlled，phase 2 trial［J］.Lancet Oncol，2016，17（12）：1720-1731.
［51］　SEKULIC A，MIGDEN M R，BASSET-SEGUIN N，GARBE C，GESIERICH A，LAO C D，et al.Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma：final update of the pivotal ERIVANCE BCC study［J］.BMC Cancer，2017，17（1）：332.
［52］　DEMICI H，WORDEN F，NELSON C C，ELNER V M，KAHANA A.Efficacy of vismodegib （erivedge） for basal cell carcinoma involving the orbit and periocular area［J］.Ophthal Plast Reconstr Surg，2015，31（6）：463-466.
［53］　JAIN S，SONG R，XIE J.Sonidegib：mechanism of action，pharmacology，and clinical utility for advanced basal cell carcinomas［J］.Onco Targets Ther，2017，10：1645-1653.
［54］　MIGDEN M R，GUMINSKI A，GUTZMER R，DIRIX L，LEWIS K D，COMBEMALE P，et al.Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma （BOLT）：a multicentre，randomised，double-blind phase 2 trial［J］.Lancet Oncol，2015，16（6）：716-728.
［55］　MASTERS G A，KRILOY L，BAILEY H H，BROSE M S，BURSTEIN H，DILLER L R，et al.Clinical cancer advances 2015：Annual report on progress against cancer from the American Society of Clinical Oncology［J］.J Clin Oncol，2015，33（7）：786-809.
［56］　Services USDoHaH.U.S.Food and Drug Administration 2015.［consultado 24 Jul 2015］.Disponible en：http：//www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm455862.htm
［57］　LANOUE J，GOLDENBERG G.Basal cell carcinoma：a com-prehensive review of existing and emerging nonsurgical therapies［J］.J Clin Aesthet Dermatol，2016，9（5）：26-36.
［58］　CRAWFORD C，FEMELIUS C，YOUNG P，GROO S，AINBINDER D，et al.Application of the AJCC 7th edition carcinoma of the eyelid staging system：a medical center pathology based，15-year review［J］.Clin Ophthalmol，2011，5：1645-1648.
［59］　ZHAO Z F，WANG N，WANG D Q，LAN C J.Differences in cellular morphology and proliferation of eyelid basal cell carcinoma associated fibroblasts and normal fibroblasts［J］.Rec Adv Ophthalmol，2016，36（4）：327-330.
赵佐芳，王宁，王大庆，兰长俊.眼睑基底细胞癌相关成纤维细胞与正常成纤维细胞形态与生长增殖特性差异［J］.眼科新进展，2016，36（4）：327-330.

相似文献/References:

[1]邵毅,周召,葛倩敏.糖尿病视网膜病变及黄斑水肿诊疗规范：英国皇家眼科医师学会指南解读[J].眼科新进展,2021,41(7):601.[doi:10.13389/j.cnki.rao.2021.0125]
　SHAO Yi,ZHOU Zhao,GE Qianmin.Consensus interpretation on the diagnosis and treatment of diabetic retinopathy and diabetic macular edema by the The Royal College of Ophthalmologists[J].Recent Advances in Ophthalmology,2021,41(1):601.[doi:10.13389/j.cnki.rao.2021.0125]

更新日期/Last Update: 2019-01-04